

File No. 150741

Committee Item No. 4

Board Item No. 39

COMMITTEE/BOARD OF SUPERVISORS

AGENDA PACKET CONTENTS LIST

Committee: Budget & Finance Sub-Committee

Date July 22, 2015

Board of Supervisors Meeting

Date July 28, 2015

Cmte Board

- | | | |
|-------------------------------------|-------------------------------------|--|
| <input type="checkbox"/> | <input type="checkbox"/> | Motion |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Resolution |
| <input type="checkbox"/> | <input type="checkbox"/> | Ordinance |
| <input type="checkbox"/> | <input type="checkbox"/> | Legislative Digest |
| <input type="checkbox"/> | <input type="checkbox"/> | Budget and Legislative Analyst Report |
| <input type="checkbox"/> | <input type="checkbox"/> | Youth Commission Report |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Introduction Form |
| <input type="checkbox"/> | <input type="checkbox"/> | Department/Agency Cover Letter and/or Report |
| <input type="checkbox"/> | <input type="checkbox"/> | MOU |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Grant Information Form |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Grant Budget |
| <input type="checkbox"/> | <input type="checkbox"/> | Subcontract Budget |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Contract/Agreement |
| <input type="checkbox"/> | <input type="checkbox"/> | Form 126 – Ethics Commission |
| <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | Award Letter |
| <input type="checkbox"/> | <input type="checkbox"/> | Application |
| <input type="checkbox"/> | <input type="checkbox"/> | Public Correspondence |

OTHER (Use back side if additional space is needed)

<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____
<input type="checkbox"/>	<input type="checkbox"/>	_____

Completed by: Linda Wong Date July 17, 2015

Completed by: Linda Wong Date July 23, 2015

1 [Accept and Expend Grant - Public Health Foundation Enterprises - San Francisco Bay
2 Clinical Trials Unit - \$211,225]

3 **Resolution retroactively authorizing the San Francisco Department of Public Health to**
4 **accept and expend a grant in the amount of \$211,225 from Public Health Foundation**
5 **Enterprises to participate in a program entitled "San Francisco Bay Clinical Trials Unit"**
6 **for the period of December 1, 2014, through November 30, 2015.**

7
8 WHEREAS, Public Health Foundation Enterprises is the recipient of a grant award from
9 National Institutes of Health supporting the San Francisco Bay Clinical Trials Unit grant; and

10 WHEREAS, With a portion of these funds, Public Health Foundation Enterprises has
11 subcontracted with Department of Public Health (DPH) in the amount of \$211,225 for the
12 period of December 1, 2014, through November 30, 2015; and

13 WHEREAS, As a condition of receiving the grant funds, Public Health Foundation
14 Enterprises requires the City to enter into an agreement (Agreement), a copy of which is on
15 file with the Clerk of the Board of Supervisors in File No. 150741; which is hereby
16 declared to be a part of this Resolution as if set forth fully herein; and

17 WHEREAS, The purpose of this project will fund staff to be responsible for the overall
18 scientific leadership of the Clinical Trial Unit and Bridge HIV Congressional Research Service
19 and will prioritize research efforts. This project will also fund staff to oversee the overall
20 scientific, operational and administrative aspects of the demonstration project and provide
21 technical expertise and training; and

22 WHEREAS, The estimated grant amount of \$44,530 is budgeted in the FY2014-2015
23 Annual Appropriation Ordinance, an additional amount of \$166,695 was awarded from Public
24 Health Foundation Enterprises, for a total amount of \$211,225 after the AAO already was
25 approved; and

1 WHEREAS, An Annual Salary Ordinance amendment is not required as the grant
2 partially reimburses DPH for three existing positions, one Manager VIII (Job Class No. 0943)
3 at .20 FTE, one Senior Physician Specialist (Job Class No. 2232) at .5514 FTE and one
4 Supervising Physician Specialist (Job Class No. 2233) at .10 FTE for the period of December
5 1, 2014, through November 30, 2015; and

6 WHEREAS, A request for retroactive approval is being sought because DPH did not
7 receive the letter of funding allocation until April 9, 2015, for a project start date of December
8 1, 2014; and

9 WHEREAS, The budget includes a provision for indirect costs in the amount of
10 \$32,953; now, therefore, be it

11 RESOLVED, That DPH is hereby authorized to retroactively accept and expend a grant
12 in the amount of \$211,225 from Public Health Foundation Enterprises; and, be it

13 FURTHER RESOLVED, That DPH is hereby authorized to retroactively accept and
14 expend the grant funds pursuant to San Francisco Administrative Code section 10.170-1; and,
15 be it

16 FURTHER RESOLVED, That the Director of Health is authorized to enter into the
17 Agreement on behalf of the City.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

RECOMMENDED:




Barbara A. Garcia, MPA
Director of Health

APPROVED:



Office of the Mayor



Office of the Controller

File Number: _____
(Provided by Clerk of Board of Supervisors)

Grant Resolution Information Form
(Effective July 2011)

Purpose: Accompanies proposed Board of Supervisors resolutions authorizing a Department to accept and expend grant funds.

The following describes the grant referred to in the accompanying resolution:

1. Grant Title: **San Francisco Bay Clinical Trials Unit**

2. Department: **Department of Public Health
Population Health Division – HIV Bridge**

3. Contact Person: **Martin Soto** Telephone: **415-437-7029**

4. Grant Approval Status (check one):

Approved by funding agency

Not yet approved

5. Amount of Grant Funding Approved or Applied for: **\$211,225**

6a. Matching Funds Required: **\$0**

b. Source(s) of matching funds (if applicable):

7a. Grant Source Agency: **National Institutes of Health (NIH)**

b. Grant Pass-Through Agency (if applicable): **Public Health Foundation Enterprises (PHFE)**

8. Proposed Grant Project Summary:

This grant will pay for Dr. Buchbinder to be responsible for the overall scientific leadership of the Clinical Trial Unit (CTU) and Bridge HIV Congressional Research Service (CSR), and will prioritize research efforts. She will lead manuscript development at the site, assisting in research design and analysis, presentation and publication of data. This grant will pay Dr. Liu to be responsible for the overall scientific, operational and administrative aspects of the demonstration project. As the lead investigator of the San Francisco site, he will oversee overall study implementation at this site and will be responsible for study enrollment and retention, data collection, evaluation and reporting of AEs, clinical management of study participants, and quality management. This grant will pay Dr. McFarland to be responsible for providing technical expertise and training for the implementation of RDS among transwomen in Rio de Janeiro, Brazil. He will assist with the formative assessment phase to ensure that the theoretical underpinnings of RDS are met in the study population and context, standardize the procedures for implementation, monitor data quality, and assist with the specialized analyses RDS requires. Dr. McFarland will also coordinate measures and methods with the Brazilian National AIDS Program.

9. Grant Project Schedule, as allowed in approval documents, or as proposed:

Start-Date: **12/01/2014**

End-Date: **11/30/2015**

10a. Amount budgeted for contractual services: **\$0**

b. Will contractual services be put out to bid? **No, existing services**

c. If so, will contract services help to further the goals of the Department's Local Business Enterprise (LBE) requirements? **N/A**

d. Is this likely to be a one-time or ongoing request for contracting out? **N/A**

11a. Does the budget include indirect costs?

Yes

No

b1. If yes, how much? **\$32,953**

b2. How was the amount calculated? **24.03% of Salaries**

c1. If no, why are indirect costs not included? N/A

- Not allowed by granting agency
- Other (please explain):

To maximize use of grant funds on direct services

c2. If no indirect costs are included, what would have been the indirect costs?

12. Any other significant grant requirements or comments:

We respectfully request for approval to accept and expend these funds retroactive to December 01, 2014. The Department received the letter of funding allocation on April 09, 2015.

Grant Code: HCD119/1500

****Disability Access Checklist***(Department must forward a copy of all completed Grant Information Forms to the Mayor's Office of Disability)**

13. This Grant is intended for activities at (check all that apply):

- | | | |
|--|---|--|
| <input checked="" type="checkbox"/> Existing Site(s) | <input type="checkbox"/> Existing Structure(s) | <input type="checkbox"/> Existing Program(s) or Service(s) |
| <input type="checkbox"/> Rehabilitated Site(s) | <input type="checkbox"/> Rehabilitated Structure(s) | <input type="checkbox"/> New Program(s) or Service(s) |
| <input type="checkbox"/> New Site(s) | <input type="checkbox"/> New Structure(s) | |

14. The Departmental ADA Coordinator or the Mayor's Office on Disability have reviewed the proposal and concluded that the project as proposed will be in compliance with the Americans with Disabilities Act and all other Federal, State and local disability rights laws and regulations and will allow the full inclusion of persons with disabilities. These requirements include, but are not limited to:

1. Having staff trained in how to provide reasonable modifications in policies, practices and procedures;
2. Having auxiliary aids and services available in a timely manner in order to ensure communication access;
3. Ensuring that any service areas and related facilities open to the public are architecturally accessible and have been inspected and approved by the DPW Access Compliance Officer or the Mayor's Office on Disability Compliance Officers.

If such access would be technically infeasible, this is described in the comments section below:


Comments:

Departmental ADA Coordinator or Mayor's Office of Disability Reviewer:

Ron Weigelt
(Name)

Director of Human Resources and Interim Director, EEO, and Cultural Competency Programs
(Title)

Date Reviewed: 5-12-15



(Signature Required)

Department Head or Designee Approval of Grant Information Form:

Barbara A. Garcia, MPA
(Name)

Director of Health
(Title)

Date Reviewed: 5/14/15


(Signature Required)

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH
 AIDS Office Research Section
 San Francisco Bay Clinical Trial Unit
 December 01, 2014 to November 30, 2015
 Monthly Expenditure and Projection Report

Dept / Div: HPH-03
 Fund Group: 2S/CHS/GNC
 Index Code: HCHVRSRCHGR
 Grant Code: hcd119
 Grant Detail: 1500

\$183,500 SALARY CAPS PER NIH GUIDES eff 01.11.15

CATEGORY/LINE ITEM	Annual Salary	30.0%	Total Annual Sal/Frn Ben	% OF TIME	% OF PTE	Monthly Rate	Mth	Salary Budget	Frn Ben Budget	Total Budget	Co
		Annual Frn Ben									
A. PERSONNEL											
1. HIV Bridge Director 2237 5 S. Buchbinder	181,500	54,450	235,950	20.00%	0.200	15,125	12	36,300	10,890	47,190	Budget A
Sr Physican Specialist 2232 5 A. Liu	181,500	54,450	235,950	16.00%	0.160	15,125	12	29,040	8,712	37,752	Budget A
Sr Physican Specialist 2232 5 A. Liu	183,500	55,050	238,550	29.135%	0.291	15,292	12	53,463	16,038	69,501	Budget B
Sr Physican Specialist 2232 5 A. Liu	183,500	55,050	238,550	10.00%	0.100	15,292	8	12,220	3,666	15,886	Budget C
Sr Physican Specialist 2233 5 W. McFarland	183,500	55,050	238,550	10.00%	0.100	15,292	4	6,110	1,833	7,943	Budget C
3 COLA										0	
TOTAL PERSONNEL:											
											00101 SALARIES:
											137,133
											00103 MANDATORY FRINGE:
											41,139
											<u>TOTAL PERSONNEL:</u>
											<u>178,272</u>
C. TRAVEL											
1. Local Travel (02301)											
2. Out-of-Jurisdiction Travel(02101)											
Sub Total TRAVEL											
											0
											0
											<u>0</u>
D. EQUIPMENT											
1.											
Sub Total EQUIPMENT											
											0
											<u>0</u>
E. MATERIALS AND SUPPLIES											
1.											
Sub Total SUPPLIES											
											0
											<u>0</u>
F. CONTRACTUAL SERVICES (02789)											
1.											
Sub Total CONTRACTS											
											0
											<u>0</u>
G. OTHER											
1. Rent Paid to RE (08118)											
2. IS/TIS/ISD Svcs (081C5)											
3. IS/TIS/ISD Svcs (081C5)											
Sub TOTAL OTHER											
											0
											<u>0</u>
TOTAL DIRECT COST											178,272

1831

SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH
 AIDS Office Research Section
 San Francisco Bay Clinical Trial Unit
 December 01, 2014 to November 30, 2015
 Monthly Expenditure and Projection Report

Dept / Div: HPH-03
 Fund Group: 2S/CHS/GNC
 Index Code: HCHIVRSRCHGR
 Grant Code: hed119
 Grant Detail: 1500

\$183,500 SALARY CAPS PER NIH GUIDES eff 01.11.15

BUDGET SUMMARY

A & B.	TOTAL PERSONNEL (SALARIES & FRINGE)	178,272
C.	TRAVEL	0
D.	EQUIPMENT	0
E.	MATERIALS AND SUPPLIES	0
F.	CONTRACT / MOU	0
G.	OTHER	0
	DIRECT COSTS	178,272
H.	INDIRECT COSTS (24.03% of salaries)	32,953
	TOTAL BUDGET	211,225
	AWARD	211,225
	SURPLUS/(DEFICIT)	(0)

1832

San Francisco Department of Public Health (SFPDH)
AIDS Office
HIV Research Section

San Francisco Bay Clinical Trails

BUDGET JUSTIFICATION

December 01, 2014- November 30, 2015

A. PERSONNEL
B. MANDATORY FRINGE

1. 0943 – Manager VIII (HIV Bridge Director): Susan Buchbinder

Annual Salary $\$181,500 \times 0.20$ FTE for 12 month = $\$36,300$
Mandatory Fringe Benefits (@ 30%) = $\$10,890$ $\$47,190$

Dr. Buchbinder serves as the Director of Bridge HIV. She has been the PI of the previous San Francisco Department of Public Health CTU, which is now affiliated with HVTN, HPTN, and MTN. She helps direct the HVTN (through the Executive Management Team) and the HPTN (by co-chairing the Integrated Strategies Working Group). Dr. Buchbinder will be PI of the SFBay CTU with Dr. Diane Havlir, as well as being the Leader of the Bridge HIV CRS. Dr. Buchbinder will be responsible for the overall scientific leadership of the CTU and Bridge HIV CRS, and will prioritize research efforts. She will have final decision-making authority for the CRS; she and Dr. Havlir will share decision making authority for the CTU. She will oversee study implementation at the CRS, ensuring that Division Directors have the resources and skills needed to successfully carry out their protocols, and provide guidance and mentorship to them. She will lead manuscript development at the site, assisting in research design and analysis, presentation and publication of data. She will be the primary liaison to the HVTN, HPTN, and MTN. Dr. Buchbinder will provide input into local study operations including recruitment strategies, decisions about enrollment of potential study volunteers, evaluation of AEs, and quality management issues (including review of study records at the initiation of study protocols). She will review all SAEs and provide clinical cross-coverage for all HVTN study participants. She will continue to serve on the HVTN Executive Management Team, chair the HVTN Efficacy Trials Design Working Group and Investigators Group, and serve on a number of committees and working groups. She will continue to co-chair the HPTN Integrated Strategies Working Group and serve on HPTN committees. She will also chair protocols for all Networks with which she is affiliated.

2. 2232 – Sr. Physician Specialist: Albert Liu, MD
Annual Salary $\$181,500 \times 0.16$ FTE for 12 month = $\$29,040$
Mandatory Fringe Benefits (@ 30%) = $\$8,712$ $\$37,752$

2232 – Sr. Physician Specialist: Albert Liu, MD
Annual Salary $\$183,500 \times 0.29135$ FTE for 12 month = $\$53,463$

Mandatory Fringe Benefits (@ 30%) = \$16,038 \$69,501

2232 – Sr. Physician Specialist: Albert Liu, MD
Annual Salary \$183,500 x 0.10 FTE for 8 month = \$12,220
Mandatory Fringe Benefits (@ 30%) = \$3,666 \$15,886

Dr. Liu will co-chair the SFBay CTU Operations Steering Committee and be a major contributor to HPTN and MTN. He will also serve as Co-Leader of the Bridge HIV CRS, providing overarching leadership and mentorship to all of the teams. He will directly oversee all PrEP and microbicide trials conducted at Bridge HIV, including their regulatory and laboratory components, and directly supervise the clinical staff and Study Coordinator. Dr. Liu will be responsible for the overall scientific, operational and administrative aspects of the demonstration project. As the lead investigator of the San Francisco site, he will oversee overall study implementation at this site and will be responsible for study enrollment and retention, data collection, evaluation and reporting of AEs, clinical management of study participants, and quality management. Also, along with the protocol co-chairs, he will have responsibility for achieving the overall specific aims of the project, for maintaining the proposed project schedule, ensuring quality control over all aspects of this project, and data analyses and publication of results.

3. 2233 – Supervising Physician Specialist: Willi McFarland, MD
Annual Salary \$183,500 x 0.10 FTE for 4 month = \$6,110
Mandatory Fringe Benefits (@ 30%) = \$1,833 \$7,943

Willi McFarland, MD, PhD, MPH (co-Investigator) is the Director of the Center for Public Health Research (CPHR) at the San Francisco Department of Public Health and Professor of Epidemiology and Biostatistics at the University of California San Francisco (UCSF). Dr. McFarland has over 20-years' experience in sampling and recruiting hidden and hard-to-reach populations for HIV epidemiology, surveillance, and prevention research, including over 10-years' experience with respondent-driven sampling (RDS), and 11 years of experience working in Brazil. He has also been PI for several studies of transgendered persons, including a current NIH-funded study on new methods for probability-based sampling of transmen (R21HD071765). For the current application, Dr. McFarland will provide technical expertise and training for the implementation of RDS among transwomen in Rio de Janeiro, Brazil. He will assist with the formative assessment phase to ensure that the theoretical underpinnings of RDS are met in the study population and context, standardize the procedures for implementation, monitor data quality, and assist with the specialized analyses RDS requires. Dr. McFarland will also coordinate measures and methods with the Brazilian National AIDS Program.

Total Salaries	\$137,133
Total Fringe	\$41,139
TOTAL PERSONNEL:	\$178,272

C.	TRAVEL	\$0
D.	EQUIPMENT	\$0
E.	SUPPLIES	\$0
F.	CONTRACTUAL	\$0
G.	OTHER	\$0
	TOTAL DIRECT COSTS	\$178,272
H.	INDIRECT COSTS (24.03% of Salaries)	\$32,953
	TOTAL BUDGET:	\$211,225



12801 Crossroads Parkway South, Suite 200 City of Industry, CA 91746 P: 800.201.7320 F: 562.692.6950 www.phfe.org

Public Health
Foundation
Enterprises

SUBCONTRACT AMENDMENT BETWEEN
PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.
AND
CITY AND COUNTY OF SAN FRANCISCO

Subcontract Amendment 1
0325.015.001
SF Bay Area CTU

Article 4 – Payment for Services:

The maximum amount payable shall not exceed \$211,225. This is an increase of \$110,582 over the budget in the executed agreement dated December 1, 2014. This increase is reflected in the attached revised Exhibits B.

Exhibit D – Form of Invoice:

Final invoices must be signed, marked "Final," and have the statement, "This final invoice represents that all deliverables have been met."

All other terms and conditions of this agreement remain in full force and effect.

Authorized signatures completing Subcontract Amendment 1 are provided below.

For Public Health Foundation Enterprises, Inc.:

DocuSigned by: <i>Peter Dale</i>	4/9/2015
<hr/> Peter Dale, Director, Contract and Grant Management	Date

For the City and County of San Francisco:

<i>Tomas Aragón</i>	4/7/15
<hr/> Tomas Aragón, Director, Population Health Division	Date

Exhibit B: Budget C

Brazil 0325.015.908	Principal Investigator/Program Director (Last, first, middle):	Buchbinder, Susan
FROM		THROUGH
12/1/2014		11/30/15
DETAILED BUDGET FOR NEXT BUDGET PERIOD - DIRECT COSTS ONLY		GRANT NUMBER
		UM1A1069496

List PERSONNEL (Applicant organization only)
 Use Cal, Acad, or Summer to Enter Months Devoted to Project
 Enter Dollar Amounts Requested (omit cents) for Salary Requested and Fringe Benefits

NAME	ROLE ON PROJECT	Cal. Mths	Acad. Mths	Summ. Mths	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
Albert Liu	co-investigator	0.80	10% for 8 months		12,220	3,666	15,886
Willie McFarland	co-investigator	0.40	10% for 4 months		6,110	1,833	7,943

Project Begins 4.1.15

NAME	ROLE ON PROJECT	Cal. Mths	Acad. Mths	Summ. Mths	SALARY REQUESTED	FRINGE BENEFITS	TOTAL
					18,330	5,499	23,829

CONSULTANT COSTS		
EQUIPMENT		0
SUPPLIES Clinical/Lab Supplies		0
TRAVEL Domestic Conference for 2 Investigators		
PATIENT CARE COSTS	INPATIENT	
	OUTPATIENT	
ALTERATIONS AND RENOVATIONS		
OTHER EXPENSES		0
SUBTOTAL DIRECT COST FOR NEXT BUDGET PERIOD		23,829
CONSORTIUM/CONTRACTUAL COSTS	DIRECT COSTS	0
CONSORTIUM/CONTRACTUAL COSTS	SFDPH Indirects 24.03% of Salary	4,405
TOTAL DIRECT COSTS FOR NEXT BUDGET PERIOD		28,234



Public Health Foundation Enterprises
A 501(c)(3) Nonprofit Organization

12801 Crossroads Parkway South, Suite 200 City of Industry, CA 91746 P: 800.201.7320 F: 562.692.6950 www.phfe.org

[SUBCONTRACT/SUBAWARD] AGREEMENT BETWEEN
PUBLIC HEALTH FOUNDATION ENTERPRISES, INC.
AND

THE CITY AND COUNTY OF SAN FRANCISCO
[SUBCONTRACTOR/SUBAWARDEE NAME]

This [Subcontract/Sub-Award] Agreement (this "Agreement") is made and entered into as of December 1, 2014 by and between PUBLIC HEALTH FOUNDATION ENTERPRISES, INC., a 501(c)(3) California nonprofit corporation (hereinafter referred to as "PHFE"), and the party identified in Section 1 below (hereinafter be referred to as "Subcontractor/Subawardee").

RECITALS

- A. PHFE has been granted an award by National Institutes of Health (the "Funding Agency"), under contract number 5UM1A1069496-09 (the "Funding Award Agreement") under which PHFE and its subcontractors and subawardees will See Exhibit A (the "Program");
- B. Subcontractor/Subawardee has expertise in the areas of See Exhibit A, which expertise can assist PHFE to perform its obligations under the Funding Award Agreement; and
- C. PHFE desires to engage the services of Subcontractor/Subawardee to assist PHFE in the performance of certain of its obligations under the Funding Award Agreement as set forth herein.

AGREEMENT

1. IDENTITIES OF PARTIES.

SUBCONTRACTOR/SUBAWARDEE: Please complete:

Legal Name of Subcontractor/Subawardee: City and County of San Francisco

DBA of Subcontractor/Subawardee: SFDPH

Type of Entity:	Sole Proprietorship	Partnership
	Corporation	Limited Liability Company

State of Organization (if an entity): California

Address: 101 Grove St, Rm 402

City/State/Zip: San Francisco, CA 94102

Business Telephone: (415) 554-2778

Social Security or Employer Identification Number:

License Number and Expiration Date, if any: 94-6000417

Email Address: sajid.shaik@sfdph.org

Name of Principal Investigator/Project Coordinator: Susan Buchbinder

Phone Number of Principal Investigator/Project Coordinator: (415) 437-7479

Is Subcontractor/Subawardee required to file a Single Audit with the Federal Government?
(Required for parties who receive Federal funds in the aggregate amount of \$500,000 or more): Please complete:

Yes No

If yes, has Subcontractor/Subawardee filed the required Single Audit?

Yes No

(If yes, submit copy to PHFE prior to signing this Agreement)

Download A-133 at <http://sfcontroller.org/index.aspx?page=402>

PHFE:

Public Health Foundation Enterprises, Inc.
12801 Crossroads Parkway South, Suite 200
City of Industry, CA, 91746-3505
Main Telephone Number (562) 699-7320

Program Name: SF Bay Clinical Trials Unit

Program/CID #: 0325.015.001 CFDA: 93.855 (One per agreement)

Contracts Manager Name: Shane Vigil

Contracts Manager Email Address: svigil@phfe.org

Program Director Name: Susan Buchbinder Telephone Number: (415) 437-7407

Program Director Email: Susan.Buchbinder@sfdph.org

Initials
PHFE PD
Subcontractor/Subawardee BS

that all employment related decisions are made in conformance with all such statutes, laws, rules and regulations; and

(iv) unless it is exempt from doing so, comply with 45 CFR Part 76, Appendix B-Certification Regarding Debarment, Suspension, and Ineligibility, Voluntary Exclusion-Lower Tier Covered Transactions.

(d) HIPAA Business Associate Agreement. If the Health Insurance Portability and Accountability Act of 1996, as amended ("HIPAA") is applicable to the Services, Subcontractor/Subawardee shall execute and deliver PHFE's standard Business Associate Agreement as required by HIPAA.

(e) Lower-tier Subcontractors/Subawardees. Subcontractor/Subawardee shall incorporate all of the terms and conditions of this Agreement into all lower-tier subcontracts that Subcontractor/Subawardee may enter into in connection with this Agreement, and shall ensure that all such lower-tier subcontractors/subawardees and their personnel comply with all of the requirements of this Agreement applicable to Subcontractor/Subawardee, and all of the rules, requirements and restrictions set forth in the Funding Award Agreement, including the Flow Down Provisions, that are applicable to such lower-tier subcontractors'/subawardees' activities.

4. PAYMENT FOR SERVICES

(a) Budget. The total compensation and reimbursements payable to Subcontractor/Subawardee hereunder shall be as set forth in the detailed budget for the Services attached hereto as Exhibit B (the "Budget"), which is made a part hereof and incorporated herein by reference, which Budget is as set forth in the Funding Award Agreement. The maximum amount payable to Subcontractor/Subawardee hereunder shall not exceed the maximum amount set forth in the Budget.

(b) Must Stay Within Budget Time Periods. Subcontractor/Subawardee shall be compensated only for Services actually performed by Subcontractor/Subawardee and within the appropriate time period set forth in the Budget.

(c) Approval of Services by PHFE. All Services must be completed to the satisfaction of PHFE in order to be entitled to payment hereunder.

(d) Funds Available to PHFE. PHFE shall not be obligated to make payment under this Agreement unless the corresponding funds are disbursed to PHFE under the Funding Award Agreement. In the event that PHFE has made payment to Subcontractor/Subawardee under this Agreement and PHFE subsequently does not receive from the Funding Agency for any reason the corresponding payment for the Services performed by Subcontractor/Subawardee or expenses incurred by Subcontractor/Subawardee, then Subcontractor/Subawardee shall refund such payment to PHFE within ten (10) days after written notice from PHFE.

PHFE BB
Subcontractor/Subawardee

(e) Billing of Expenses and Costs. All expenses and costs shall be billed in accordance with the approved budget. Expenses incurred after the expiration or termination of this Agreement shall be disallowed. Subcontractor/Subawardee shall submit its final invoice no later than 30 days after the date of expiration of the term or termination of this Agreement.

(f) Budget Modifications. The Budget may be modified only by written agreement of PHFE and Subcontractor/Subawardee and the prior written approval of the Funding Agency.

5. INVOICING PROCEDURES

(a) Approval by Funding Agency. If required under the Funding Award Agreement, Subcontractor/Subawardee must first submit all timesheets and invoices to the Funding Agency for approval by the Funding Agency. After the Funding Agency has approved a timesheet and invoice submitted by Subcontractor/Subawardee, Subcontractor/Subawardee shall submit the same to PHFE.

(b) Address for Invoices. Subcontractor/Subawardee shall send all timesheets and invoices to the attention of the PHFE Project Director at the address set forth in Section 1 above.

(c) Invoicing Period. All invoices shall be submitted not more frequently than monthly, in arrears and must be submitted to PHFE within 30 days after the end of the applicable month or within 15 days after approval by the Funding Agency (if applicable), whichever is later. All final invoices must be received within 30 days of the expiration or termination of this Agreement or within such earlier time period as PHFE may require. If any invoices are not submitted within such time periods, Subcontractor/Subawardee waives (in PHFE's discretion) all rights to payment under such invoices.

(d) Formatting and Requirements of Invoices. All invoices shall be submitted in the form attached hereto as Exhibit D, as it may be modified by PHFE from time to time.

6. TERM AND TERMINATION

(a) Term. Unless earlier terminated as provided herein, the term of this Agreement shall be from December 1, 2014 to November 30, 2015 (the "Term").

(b) Termination Without Cause. Without cause, PHFE may terminate this Agreement by giving 30 days prior written notice to Subcontractor/Subawardee of its intent to terminate this Agreement without cause.

(c) Termination for Cause. With reasonable cause, either party may terminate this Agreement effective immediately upon the giving of written notice of termination for cause. Reasonable cause shall include:

i. A material violation or breach of this Agreement by the other party which is not cured within 15 days after written notice from the terminating party;

ii. Any act of the other party that exposes the terminating party to liability to others for personal injury or property damage or any other harm, damage or injury; or

iii. If either party receives notice from the Funding Agency of the cancellation or termination of, or reduction of funding under, the Funding Award Agreement affecting the Services.

(d) Termination for Lack of Funding. PHFE may terminate this Agreement if for any reason the funding available under the Funding Award Agreement is withdrawn, limited, or impaired.

(e) Cessation Upon Termination. On the effective date of termination, Subcontractor/Subawardee shall cease all further Services under this Agreement, and Subcontractor/Subawardee shall cancel as many outstanding obligations as possible and not incur any additional obligations.

(f) Payment After Termination. Subject to the terms and conditions set forth in this Agreement, upon termination of this Agreement, provided, that PHFE has received the corresponding funds from the Funding Agency under the Funding Award Agreement, PHFE shall pay for any reasonable non-cancellable obligations properly incurred by Subcontractor/Subawardee under this Agreement and in accordance with the Budget prior to termination, and shall pay any amounts due to Subcontractor/Subawardee and properly invoiced under this Agreement for Services performed prior to termination; provided, that if PHFE has terminated this Agreement for reasonable cause under Section 6(c) above, then PHFE shall have the right to offset and deduct from any payments due to Subcontractor/Subawardee hereunder any damages or losses incurred by PHFE as a result of such violation or breach.

(g) Return of Materials. Upon the expiration or termination of this Agreement, Subcontractor/Subawardee shall immediately promptly return to PHFE all computers, cell phones, smart phones, computer programs, files, documentation, user data, media, related material and any and all other Confidential Information (as defined in below) of PHFE and all Work Product (as defined below). PHFE shall have the right to withhold final payment to Subcontractor/Subawardee until all such items are returned to PHFE.

(h) Surviving Provisions. The provisions of Sections 7 through 16, and any other sections that by their nature should or are intended to survive the expiration or termination of this Agreement shall survive and the parties shall continue to comply with the provisions of this Agreement that survive.

7. REPRESENTATIONS AND WARRANTIES. Subcontractor/Subawardee represents, warrants and covenants to PHFE as follows:

(Rev July 1, 2012)

Page 7 of 23

initials
PHFE PD
Subcontractor/Subawardee SS

(a) Ownership of Work Product. Subcontractor/Subawardee agrees that, as between PHFE and Subcontractor/Subawardee, all discoveries, ideas, inventions, and information that Subcontractor/Subawardee may develop (either alone or in conjunction with others), information or work product developed wholly or partially by Subcontractor/Subawardee as part of or related to Subcontractor's/subawardee's retention by PHFE hereunder (including all intermediate and partial versions thereof) or the performance of the services hereunder or which existence Subcontractor/Subawardee may discover while retained by PHFE, including any software, platforms, all ideas, designs, marks, logos, and content relating thereto, whether or not subject to patent, copyright or trademark or other intellectual property protections including without limitation, any scripts, prototypes, other components (collectively the "Work Product"), shall be the sole property of PHFE upon its creation and (in the case of copyrightable works) upon its fixation in a tangible medium of expression.

(b) Assignment. Subcontractor/Subawardee hereby forever assigns to PHFE all right, title and interest in any Work Product designed and/or developed by Subcontractor/Subawardee or otherwise delivered to PHFE as part of or related to Subcontractor's/Subawardee's retention with PHFE. The Work Product shall be the sole property of PHFE, and all copyrightable and patentable aspects of the Work Product are to be considered "works made for hire" within the meaning of the Copyright Act of 1976, as amended (the "Act"), of which PHFE is to be the "author" within the meaning of such Act. All such copyrightable and patentable works, as well as all copies of such works in whatever medium fixed or embodied, shall be owned exclusively by PHFE on their creation, and Subcontractor/Subawardee hereby expressly disclaims any interest in any of them. In the event (and to the extent) that any Work Product or any part or element of them, is found as a matter of law not to be a "Work Made For Hire" within the meaning of the Act, Subcontractor/Subawardee hereby assigns to PHFE the sole and exclusive right, title and interest in and to all such works, and all copies of any of them, without further consideration, and, if such assignment is invalid, Subcontractor/Subawardee hereby grants PHFE a non-exclusive, worldwide, perpetual, fully paid-up, irrevocable, right and license to use, reproduce, make, sell, perform and display (publicly or otherwise), and distribute, and modify and otherwise make derivative works of Subcontractor/Subawardee's Work Product and to authorize third parties to perform any or all of the foregoing, including through multiple tiers of sublicenses.

(c) Moral Rights Waiver. For purposes of this subsection, "Moral Rights" means any rights of paternity or integrity, any right to claim authorship of the Work Product, to object to any distortion, mutilation or other modification of, or other derogatory action in relation to, the Work Product, whether or not such would be prejudicial to Subcontractor's/Subawardee's honor or reputation, and any similar right, existing under judicial or statutory law of any country in the world, or under any treaty, regardless whether or not such right is denominated or generally referred to as a "Moral" right. Subcontractor/Subawardee hereby irrevocably transfers and assigns to PHFE any and all Moral Rights that Subcontractor/Subawardee may have in the Work Product. Subcontractor/Subawardee also hereby forever waives and agrees never to assert any and all Moral Rights it may have in the Work Product, even after termination of Subcontractor's/Subawardee's work on behalf of PHFE as part of or related to Subcontractor's/Subawardee's retention with PHFE.

(d) No Liens. Subcontractor/Subawardee shall deliver all Work Product to PHFE free and clear of any and all claims, rights and encumbrances of third parties.

(e) Assignment Documents. Subcontractor/Subawardee will cooperate with PHFE, with PHFE's approval and at PHFE's expense, in obtaining patent, copyright, trademark or other statutory protections for the Work Product in each country in which one or more is sold, distributed or licensed, and in taking any enforcement action, including any public or private prosecution, to protect PHFE's intellectual property rights in or to the Work Product. Subcontractor/Subawardee hereby grants PHFE the exclusive right, and appoints PHFE as attorney-in-fact, to execute and prosecute in Subcontractor's/Subawardee's name as author or inventor or in PHFE's name as assignee, any application for registration or recordation of any copyright, trademark, patent or other right in or to the Work Product, and to undertake any enforcement action with respect to any Work Product. With PHFE's approval and at PHFE's expense, Subcontractor/Subawardee will execute such other documents of registration and recordation as may be necessary to perfect in PHFE, or protect, the rights assigned to PHFE hereunder in each country in which PHFE reasonably determines to be prudent.

(f) No Infringement. Subcontractor/Subawardee represents and warrants that any Work Product delivered to PHFE hereunder will be developed by Subcontractor/Subawardee and shall not infringe or violate any patents, copyrights, trademarks, trade secrets or other proprietary rights of any third party.

(g) No Harmful Code. With respect to the website and any computer programs or software code ("Software") included in the Services hereunder, Subcontractor/Subawardee represents and warrants that: (i) the Software and its media shall contain no computer instructions or inappropriate functions whose purpose or result is to disrupt, damage or interfere with PHFE's or its affiliates' or their customers' use of or access to the Software or any of their data, programs or computer or telecommunications facilities and (ii) unless expressly authorized in writing by PHFE, such Software shall not contain any mechanism which electronically notifies Subcontractor/Subawardee of any fact or event, nor contain any key, node lock, time-out, logic bomb or other function, implemented by any means, which may restrict PHFE's or its affiliates' or customers' use of or access to the Software or any other programs, data or equipment.

(h) Rights of Funding Agency and Federal Government. All rights to the Work Product assigned or granted to PHFE hereunder shall be subject to any rights of the Funding Agency under the Funding Award Agreement and any rights of the United States Federal Government under applicable laws and regulations.

10. PUBLICATIONS

(a) Right to Publish Works. Subcontractor/Subawardee may, with PHFE's and the Funding Agency's prior written consent, publish articles written by Subcontractor/Subawardee in connection with the Services performed by Subcontractor/Subawardee hereunder. Subcontractor/Subawardee shall submit all such articles for review by PHFE and the Funding Agency at least 60 days prior to the proposed publication date.

PHFE
Subcontractor/Subawardee BS

(b) Acknowledgment in Publications. On any publication approved by PHFE and the Funding Agency as described above, Subcontractor/Subawardee shall place an acknowledgment of federal government support, and shall include a disclaimer, as appropriate, as follows: "The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of Public Health Foundation Enterprises, Inc. or [Name of Funding Agency]".

(c) Use of PHFE's or Funding Agency's Name. Subcontractor/Subawardee shall not use in any manner PHFE's name, logo or trademarks without PHFE's prior written consent. Subcontractor/Subawardee shall not use in any manner the Funding Agency's name, logo or trademarks without the Funding Agency's prior written consent.

11. INDEMNIFICATION

(a) By Subcontractor/Subawardee. Subcontractor/Subawardee hereby agrees to indemnify, hold harmless and defend PHFE, its board of trustees, officers, directors, agents, contractors and employees from any and all claims, causes of action, costs, demands, expenses (including attorney's fees and costs), losses, damages, injuries, and liabilities arising from (i) any accident, death, or injury whatsoever or however caused to any person or property arising out of the intentional action or negligence of Subcontractor/Subawardee (or its agents, subcontractors or employees), (ii) Subcontractor's/Subawardee's (or its agents', subcontractors' or employees') violation of any federal, state or local law or regulation, (iii) the breach by Subcontractor/Subawardee (or its agents, subcontractors or employees) of any its representations, warranties or agreements under this Agreement or (iv) any claims that the Work Product, or any element thereof, infringes the intellectual, privacy or other rights of any party.

(b) By PHFE. PHFE hereby agrees to indemnify, hold harmless and defend Subcontractor/Subawardee, its officers, directors, agents, contractors and employees from any and all claims, causes of action, costs, demands, expenses (including attorney's fees and costs), losses, damages, injuries, and liabilities arising from (i) any accident, death, or injury whatsoever or however caused to any person or property arising out of the intentional action or negligence of PHFE, (ii) PHFE's violation of any federal, state or local law or regulation or (iii) the breach by PHFE of any its representations, warranties or agreements under this Agreement.

12. INSURANCE

(a) Required Coverages. Subcontractor/Subawardee shall, unless otherwise agreed in writing by PHFE, maintain: (i) Workers' Compensation insurance, (ii) Professional Liability Insurance and Commercial General Liability Insurance (including broad form contractual and automobile liability coverage), with minimum limits of ONE MILLION DOLLARS (\$1,000,000) combined single limit per occurrence, and (iii) Automobile Liability on each automobile owned by him/her/it or his/her/its agents, subcontractors/subawardees or employees, which is used at any time to carry out Subcontractor's/Subawardee's duties hereunder, with minimum limits of \$100,000 per person

PHFE
Subcontractor/Subawardee

Initials
PD
SS

and \$300,000 per occurrence for bodily injury. If higher or additional coverages are required under the Flow Down Provisions, Subcontractor/Subawardee shall procure such coverages.

(b) Additional Insureds. All such insurance shall provide that Subcontractor's/Subawardee's insurance is primary and not contributory, shall protect Subcontractor/Subawardee, PHFE and the Funding Agency and their affiliates from claims for personal injury (including bodily injury and death) and property damage which may arise from or in connection with the performance of the Services hereunder, or from or out of any negligent act or omission of Subcontractor/Subawardee, its officers, directors, agents or employees. All such insurance shall be written by a responsible insurance company possessing B+ VII rating or better as listed in the Best Guide, shall name PHFE and the Funding Agency as additional insureds for Professional Liability, Commercial General Liability and Automobile Liability only, shall contain a waiver of subrogation with respect to the additional insureds, shall be written on an occurrence basis and shall provide that the coverage thereunder may not be reduced or canceled unless 30 days' prior written notice thereof is furnished to PHFE and the Funding Agency. Certificates of Insurance containing such waiver of subrogation or copies of policies shall be furnished to PHFE upon request.

13. CONFIDENTIALITY

(a) Confidential Information. Subcontractor/Subawardee agrees that during the course of this Agreement, Subcontractor/Subawardee may be exposed to and become aware of certain unique and confidential information and special knowledge (hereinafter "Confidential Information") provided to or developed by PHFE. Said Confidential Information includes, but is not limited to, the identity of actual and potential clients of PHFE, client lists, particular needs of each client, the manner in which business is conducted with each client, addresses, telephone numbers, and specific characteristics of clients; financial information about PHFE and/or its clients; client information reports; mailing labels; various sales and marketing information; sales report forms; pricing information (such as price lists, quotation guides, previous or outstanding quotations, or billing information); pending projects or proposals; business plans and projections, including new product, facility or expansion plans; employee salaries; contracts and wage information; mailing plans and programs; technical know-how; designs; products ordered; business methods; processes; records; specifications; computer programs; accounting; and information disclosed to PHFE by any third party which PHFE is obligated to treat as confidential and/or proprietary. This Confidential Information derives independent actual or potential economic value from not being generally known to the public or to other persons, who can obtain economic value from its disclosure or use, is not readily available through any source other than PHFE and is the subject of reasonable efforts to maintain secrecy. Since Subcontractor/Subawardee may be exposed to and become aware of said Confidential Information and, because of its unique and confidential nature, the parties hereto desire to afford PHFE protection against its unauthorized use or its use in any manner detrimental to PHFE. Therefore, Subcontractor/Subawardee shall not disclose in any manner whatsoever any of the aforesaid Confidential Information, directly or indirectly, or use it in any way whatsoever, either during this Agreement or at any time thereafter, except as required in the course of Subcontractor's/Subawardee's work with PHFE or except as otherwise provided in this Agreement. Further, Subcontractor/Subawardee shall develop and maintain procedures and

Initials
PHFE PD
Subcontractor/Subawardee SS

and consistent with the laws of the State of California without giving effect to its conflicts of laws principals. Such laws shall apply in all respects, including statutes of limitation, to any disputes or controversies arising out of or pertaining to this Agreement. The sole, exclusive and proper venue for any proceedings brought to interpret or enforce this Agreement or to obtain a declaration of the rights of the parties hereunder shall be Los Angeles County, California. Each of the parties hereto submits to the exclusive personal jurisdiction of the courts located in Los Angeles County, California and waives any defense of forum non conveniens.

(c) Equitable Relief. In light of the irreparable harm to PHFE that a breach by Subcontractor/Subawardee of Sections 9, 10, 13 and 14 of this Agreement would cause, in addition to other remedies set forth in this Agreement and other relief for violations of this Agreement, PHFE shall be entitled to enjoin Subcontractor/Subawardee from any breach or threatened breach of such Sections, to the extent permitted by law and without bond.

(d) Binding Agreement. All terms, conditions and covenants to be observed and performed by the parties hereto shall be applicable to and binding upon their respective agents, employees, heirs, executors, administrators, affiliates, subsidiaries, associates, employees, successors and assigns.

(e) Captions. All captions (section headings) set forth herein are inserted only as a matter of convenience and for reference, and shall not affect the interpretation of this Agreement.

(f) Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which, when taken together, shall constitute one and the same document.

(g) Additional Documents. The parties hereto each agree that they shall execute and, if appropriate, acknowledge any and all additional and other documents, instruments and writings which may be reasonably requested by the other party in order to fully carry out the intent and purpose of this Agreement.

(h) Attorneys' Fees; Costs. In the event that any suit in law or equity, arbitration or other formal proceeding is instituted by any party to enforce or interpret any part of this Agreement, or to recover damages for breach thereof, the prevailing party shall, in addition to any such other relief available to such party, be entitled to recover costs of suit incurred therein, and to also recover as an element of such costs (but not as damages) reasonable attorneys' fees incurred by such prevailing party.

(i) Entire Agreement. This Agreement, and all documents referred to in it, or incorporated in it, is an integrated document containing and expressing all terms, covenants, conditions, warranties and agreements of the parties relating to the subject matter hereof. No other or prior agreements or understandings, written or oral, pertaining to the same shall be valid or of any force or effect.

In the case of Subcontractor, addressed to:

San Francisco Department of Public Health
1380 Howard St
San Francisco, CA 94103
 Attention: Sajid Shaikh
 Facsimile: (415) 503-4710
 Email: sajid.shaikh@sfdph.org

Any such notice shall be deemed to have been received by the addressee, and service thereof shall be deemed effective, five (5) days following deposit thereof with the United States Postal Service, or upon actual receipt, whichever first occurs, unless the address for delivery is not within one of the United States or its territories or possessions, in which case service shall be effective seven (7) days following deposit, or upon actual receipt, whichever first occurs.

(n) Remedies Non-Exclusive. Except where otherwise expressly set forth herein, all remedies provided by this Agreement shall be deemed to be cumulative and additional and not in lieu of or exclusive of each other or of any other remedy available to the respective parties at law or in equity.

(o) Severability. If any term, provision, condition or other portion of this Agreement is determined to be invalid, void or unenforceable by a forum of competent jurisdiction, the same shall not affect any other term, provision, condition or other portion hereof, and the remainder of this Agreement shall remain in full force and effect, as if such invalid, void or unenforceable term, provision, condition or other portion of this Agreement did not appear herein.

(p) Limitation of Liability. Except for a breach of sections 9 and 13 above and except to the extent included in a party's indemnification obligations under Section 11 above, in no event shall any party be liable to the other for any indirect, special, incidental, punitive or consequential damages, whether based on breach of contract, tort (including negligence), or otherwise, and whether or not that party has been advised of the possibility of such damage.

(q) Non-Assignability. None of the parties shall assign, transfer, sell, encumber, hypothecate, alienate or otherwise dispose of this Agreement, or any right, title or interest to or in this Agreement, nor shall a party delegate any duty or obligation to be performed hereunder, without the express written consent of the other party having been first obtained, except that any party may assign this Agreement without the consent of the other party in the case of a reorganization, merger, consolidation, or sale of all or substantially all of its assets so long as the assignee expressly assumes all of the obligations of the assignor under this Agreement. Notwithstanding the foregoing, PHFE may assign this Agreement to an affiliate of PHFE without the

Initials
 PD
 PHFE
 Subcontractor/Subawardee SS

consent of the other party. Any attempt to assign this Agreement other than as permitted above shall be null and void.

(r) Signing Person. The individuals signing this Agreement on behalf of an entity represents and warrants that he/she has authority to bind such entity to this Agreement.

[Signatures follow on next page]

EXHIBIT A
TO SUBCONTRACT/SUBAWARD AGREEMENT

Scope of Work (SOW)

Dr. Buchbinder is Director of Bridge HIV. She has been the PI of the previous San Francisco Department of Public Health CTU, which is now affiliated with HVTN, HPTN, and MTN. She helps direct the HVTN (through the Executive Management Team) and the HPTN (by co-chairing the Integrated Strategies Working Group). Dr. Buchbinder will be PI of the SF Bay CTU with Dr. Diane Havlir, as well as being the Leader of the Bridge HIV CRS. Dr. Buchbinder will be responsible for the overall scientific leadership of the CTU and Bridge HIV CRS, and will prioritize research efforts. She will have final decision-making authority for the CRS; she and Dr. Havlir will share decision-making authority for the CTU. She will oversee study implementation at the CRS, ensuring that Division Directors have the resources and skills needed to successfully carry out their protocols, and provide guidance and mentorship to them. She will lead manuscript development at the site, assisting in research design and analysis, presentation and publication of data. She will be the primary liaison to the HVTN, HPTN, and MTN. Dr. Buchbinder will provide input into local study operations including recruitment strategies, decisions about enrollment of potential study volunteers, evaluation of AEs, and quality management issues (including review of study records at the initiation of study protocols). She will review all SAEs and provide clinical cross-coverage for all HVTN study participants. She will continue to serve on the HVTN Executive Management Team, chair the HVTN Efficacy Trials Design Working Group and Investigators Group, and serve on a number of committees and working groups. She will continue to co-chair the HPTN Integrated Strategies Working Group and serve on HPTN committees. She will also chair protocols for all Networks with which she is affiliated.

Dr. Liu will co-chair the SF Bay CTU Operations Steering Committee and be a major contributor to HPTN and MTN. He will also serve as Co-Leader of the Bridge HIV CRS, providing overarching leadership and mentorship to all of the teams. He will directly oversee all PrEP and microbicide trials conducted at Bridge HIV, including their regulatory and laboratory components, and directly supervise the clinical staff and Study Coordinator. Dr. Liu will be responsible for the overall scientific, operational and administrative aspects of the upcoming PrEP demonstration project. As the lead investigator of the San Francisco site, he will oversee overall study implementation at this site and will be responsible for study enrollment and retention, data collection, evaluation and reporting of AEs, clinical management of study participants, and quality management. Also, along with the protocol co-chairs, he will have responsibility for achieving the overall specific aims of the project, for maintaining the proposed project schedule, ensuring quality control over all aspects of this project, and data analyses and publication of results.

EXHIBIT B
TO SUBCONTRACT/SUBAWARD AGREEMENT

Budget

Budget follows on next page

EXHIBIT C
TO SUBCONTRACT/SUBAWARD AGREEMENT
FLOW DOWN PROVISIONS

See following pages.

PHFE

Initials PD

Subcontractor/Subawardee SS

Notice of Award



Multi-Component Research Project Co-op Agreements Issue Date: 11/17/2014
Department of Health and Human Services
National Institutes of Health
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES



Grant Number: 5UM1AI069496-09
FAIN: UM1AI069496

Principal Investigator(s):
Susan Buchbinder (contact), MD
Diane V Havlir, MD

Project Title: San Francisco Bay Clinical Trials Unit

PETER DALE
PUBLIC HEALTH FOUNDATION ENTERPRISES, INC
12801 CROSSROADS PARKWAY SOUTH
SUITE 200
CITY OF INDUSTRY, CA 917466050

Award e-mailed to: pdale@phfe.org

Budget Period: 12/01/2014 – 11/30/2015
Project Period: 03/02/2007 – 11/30/2020

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$1,264,362 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to PUBLIC HEALTH FOUNDATION ENTERPRISES in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number UM1AI069496. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Michael W. Fato
Grants Management Officer
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Additional information follows

SECTION I – AWARD DATA – 5UM1A1069496-09

Award Calculation (U.S. Dollars)

Salaries and Wages	\$420,554
Fringe Benefits	\$126,166
Supplies	\$5,094
Travel Costs	\$12,852
Other Costs	\$10,000
Consortium/Contractual Cost	\$627,632

Federal Direct Costs	\$1,202,298
Federal F&A Costs	\$62,064
Approved Budget	\$1,264,362
Federal Share	\$1,264,362
TOTAL FEDERAL AWARD AMOUNT	\$1,264,362

AMOUNT OF THIS ACTION (FEDERAL SHARE) \$1,264,362

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
9	\$1,264,362	\$1,264,362
10	\$1,264,362	\$1,264,362
11	\$1,264,362	\$1,264,362
12	\$1,264,362	\$1,264,362
13	\$1,264,362	\$1,264,362
14	\$1,264,362	\$1,264,362

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

Fiscal Information:

CFDA Number: 93.855
 EIN: 1952557063A1
 Document Number: UAI069496B

PMS Account Type: P (Subaccount)
 Fiscal Year: 2015

IC	CAN	2015	2016	2017	2018	2019	2020
AI	8472297	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

NIH Administrative Data:

PCC: A28Z / OC: 414P / Released: FATOM 11/14/2014
 Award Processed: 05/08/2014 01:52:21 PM

SECTION II – PAYMENT/HOTLINE INFORMATION – 5UM1A1069496-09

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

SECTION III – TERMS AND CONDITIONS – 5UM1A1069496-09

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- a. The grant program legislation and program regulation cited in this Notice of Award.

- b. Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.
- c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
- d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the Central Contractor Registration. Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) UM1A1069496. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

This award is not subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

This award provides support for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register "applicable clinical trials" on the ClinicalTrials.gov Protocol Registration System Information Website. NIH encourages registration of all trials whether required under the law or not. For more information, see http://grants.nih.gov/ClinicalTrials_fdaaa/

This award provides support for one or more NIH defined Phase III Clinical Trials. The NIH Policy for research supported as an NIH Phase III Clinical Trial has been amended in Section II.B. of the NIH Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended October 2001 (see http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm).

A description of plans to conduct analyses, as appropriate, by sex/gender and racial/ethnic groups must be included in clinical trial protocols. Cumulative subject accrual and progress in conducting subset analyses must be reported to NIH in the annual Progress Reports. Final analyses of sex/gender and racial/ethnic differences must be reported in the required Final Progress Report or Competitive Renewal Applications (or Contract Renewals/Extensions) as stated in Section II.B. of the Guidelines.

Treatment of Program Income:
Additional Costs

SECTION IV – AI Special Terms and Conditions – 5UM1A1069496-09

This award provides core funding for the following Clinical Research Sites (CRS) in support of the following Networks:

**HPTN, HVTN, MTN
ACTG**

**Bridge CRS
UCSF CRS**

Page-4

Continued support will be based on a satisfactory evaluation at the end of a time period designated as appropriate by each Network.

Satisfactory evaluation will be based on meeting Network and NIAID/DAIDS performance standards by the end of each performance period.

The Network will assist sites to address performance or accrual deficiencies, and negotiate deadlines for demonstrating improvement as necessary

IF ANY CRS IS UNABLE TO MEET THE REQUIREMENTS OF THE NETWORK LEADERSHIP AND OPERATIONS CENTER (LOC) AND NIAID/DAIDS BY ITS NEGOTIATED DEADLINE, FUNDING MAY BE WITHDRAWN AND A PLAN TO PHASE-OUT THE CRS WILL BE ESTABLISHED.

If it is determined by NIAID/DAIDS in collaboration with the Network LOC that the CTU and/or affiliated CRS has performance or other issues, the grantee will first be notified in writing by the Network LOC. A plan of action will be developed by the Network LOC in conjunction with DAIDS including expectations for corrective actions and timelines for implementing such corrective actions.

PROTOCOL SUPPORT

Additional funding for protocol activity will be provided by the respective Network LOC(s) through sub-contracts.

KEY PERSONNEL

The following key personnel (as defined by NIAID/DAIDS) need prior NIAID/DAIDS approval before they may be replaced on the grant (Susan Buchbinder and Diane Havlir, CTU PIs and CRS Leaders for Bridge CRS and UCSF CRS respectively). Prior approval will be granted via revised NoA.

In addition, changes to the individuals who occupy the following positions: CTU Coordinator, each CRS Coordinator, and each Pharmacist(s) of Record must also be approved by DAIDS; however, these changes will not require a revised Notice of Award.

The grantee is required to follow any applicable Network policies and procedures for obtaining prior approval for changes in these positions.

All components of the CTU are required to comply with NIH, NIAID, and DAIDS policies & procedures, including NIAID Clinical Terms of Award; and affiliated Network policies & procedures. See DAIDS Clinical Research Policies and Standard Procedures located at:

<http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Pages/Default.aspx>

This award includes funds awarded for consortium activity with the University of California, San Francisco in the amount of \$515,813 (\$384,935 direct costs + \$130,878 facilities and administrative costs).

This award includes funds awarded for consortium activity with the San Francisco Department of Public Health in the amount of \$111,819 (\$94,380 direct costs + \$17,439 facilities and administrative costs).

Consortiums are to be established and administered as described in the NIH Grants Policy Statement (NIH GPS). The referenced section of the NIH Grants Policy Statement is available at http://grants.nih.gov/grants/policy/nihgps_2013/nihgps_ch15.htm# Toc271266264.

This award is issued as a Cooperative Agreement, a financial assistance mechanism in which substantial NIH scientific and/or programmatic involvement is anticipated in the performance of the activity. This award is subject to the Terms and Conditions of Award as set forth in Section VI: Award Administrative Information of RFA AI-12-018, "Clinical Trials Units for NIAID Networks (UM1)," release date 01/27/2012, which are hereby incorporated by reference as special terms and conditions of this award.

This RFA may be accessed at: <http://grants.nih.gov/grants/guide/index.html>

STAFF CONTACTS

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

Grants Management Specialist: Julia L. Shriner
 Email: julia.shriner@nih.gov Phone: 240-669-2972 Fax: 301-493-0597

Program Official: Patricia L. Jones
 Email: jonespl@mail.nih.gov Phone: 240-292-4851

SPREADSHEET SUMMARY
GRANT NUMBER: 5UM1AI069496-09

INSTITUTION: PUBLIC HEALTH FOUNDATION ENTERPRISES

Budget	Year 9	Year 10	Year 11	Year 12	Year 13	Year 14
Salaries and Wages	\$420,554	\$420,554	\$420,554	\$420,554	\$420,554	\$420,554
Fringe Benefits	\$126,166	\$126,166	\$126,166	\$126,166	\$126,166	\$126,166
Supplies	\$5,094	\$5,094	\$5,094	\$5,094	\$5,094	\$5,094
Travel Costs	\$12,852	\$12,852	\$12,852	\$12,852	\$12,852	\$12,852
Other Costs	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000	\$10,000
Consortium/Contractual Cost	\$627,632	\$627,632	\$627,632	\$627,632	\$627,632	\$627,632
TOTAL FEDERAL DC	\$1,202,298	\$1,202,298	\$1,202,298	\$1,202,298	\$1,202,298	\$1,202,298
TOTAL FEDERAL F&A	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064
TOTAL COST	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362	\$1,264,362

Facilities and Administrative Costs	Year 9	Year 10	Year 11	Year 12	Year 13	Year 14
F&A Cost Rate 1	10.8%	10.8%	10.8%	10.8%	10.8%	10.8%
F&A Cost Base 1	\$574,666	\$574,666	\$574,666	\$574,666	\$574,666	\$574,666
F&A Costs 1	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064	\$62,064

EXHIBIT D
TO SUBCONTRACT/SUBAWARD AGREEMENT
FORM OF INVOICE

Invoice format submitted in previous year is acceptable.

Initials
PHFE PD
Subcontractor/Subawardee SS

Introduction Form

By a Member of the Board of Supervisors or the Mayor

Time stamp
or meeting date

I hereby submit the following item for introduction (select only one):

- 1. For reference to Committee. (An Ordinance, Resolution, Motion, or Charter Amendment)
- 2. Request for next printed agenda Without Reference to Committee.
- 3. Request for hearing on a subject matter at Committee.
- 4. Request for letter beginning "Supervisor [] inquires"
- 5. City Attorney request.
- 6. Call File No. [] from Committee.
- 7. Budget Analyst request (attach written motion).
- 8. Substitute Legislation File No. []
- 9. Reactivate File No. []
- 10. Question(s) submitted for Mayoral Appearance before the BOS on []

Please check the appropriate boxes. The proposed legislation should be forwarded to the following:

- Small Business Commission Youth Commission Ethics Commission
- Planning Commission Building Inspection Commission

Note: For the Imperative Agenda (a resolution not on the printed agenda), use a Imperative Form.

Sponsor(s):

Supervisor Wiener


Subject:

Accept and Expend Grant- San Francisco Bay Clinical Trials Unit - \$211,225

The text is listed below or attached:

Resolution authorizing the San Francisco Department of Public Health to retroactively accept and expend a grant in the amount of \$211,225 from Public Health Foundation Enterprises to participate in a program entitled San Francisco Bay Clinical Trials Unit for the period of December 1, 2014, through November 30, 2015.

Signature of Sponsoring Supervisor: _____



For Clerk's Use Only: